Amiodarone in Atrial Fibrillation Management

Primary Role and Positioning

The European Society of Cardiology recommends amiodarone as a highly effective but second-line antiarrhythmic agent for AF rhythm control in most patients, reserved as first-line therapy specifically for those with structural heart disease, heart failure with reduced ejection fraction (HFrEF), or coronary artery disease 1, 2
The European Society of Cardiology positions amiodarone based on cardiac substrate, with amiodarone being the preferred antiarrhythmic in patients with HFrEF, severe left ventricular hypertrophy, or coronary artery disease due to its low proarrhythmic risk and safety in left ventricular dysfunction 1, 2, 3

The European Society of Cardiology recommends IV amiodarone for cardioversion of recent-onset AF in patients with structural heart disease, accepting that conversion may be delayed compared to Class IC agents 1
For pharmacological cardioversion, the European Society of Cardiology suggests using IV flecainide, propafenone, or vernakalant first in structurally normal hearts, and IV amiodarone in patients with structural heart disease 1, 2

Amiodarone is the most effective antiarrhythmic drug for maintaining sinus rhythm, with approximately 60-65% of patients remaining in sinus rhythm at one year compared to 23-38% with other agents 4, 3
The American Heart Association and European Society of Cardiology recommend using the lowest effective maintenance dose (100-200 mg daily) after appropriate loading to minimize toxicity while maintaining efficacy 4, 3

The European Society of Cardiology warns that amiodarone frequently causes extracardiac side effects with long-term use, requiring mandatory monitoring and often limiting its use as first-line therapy except in structural heart disease 1, 5, 3
The European Society of Cardiology recommends establishing baseline values before initiating amiodarone and monitoring at least every 6 months during therapy, including chest radiograph, pulmonary function tests with DLCO, thyroid function tests, liver enzymes, ECG, and ophthalmologic examination 2, 4, 3

The European Society of Cardiology recommends choosing amiodarone as initial therapy in patients with HFrEF (LVEF <40%), severe left ventricular hypertrophy, coronary artery disease, or prior MI 1, 2, 4
The European Society of Cardiology suggests avoiding amiodarone as first-line in structurally normal hearts and using flecainide, propafenone, or dronedarone instead 1, 5

The European Society of Cardiology recommends discussing catheter ablation as a first-line alternative to amiodarone in patients without structural heart disease who are candidates for both therapies, to avoid long-term amiodarone toxicity 1

The American College of Cardiology recommends intravenous amiodarone (150 mg over 10 minutes, then 0.5-1 mg/min infusion) for rate control when other measures fail or are contraindicated, particularly in patients with heart failure and AF without an accessory pathway 6, 7
IV amiodarone can be useful when beta blockers or calcium channel blockers are unsuccessful or contraindicated, with a Class IIa recommendation 8
For patients with AF and rapid ventricular response causing hemodynamic compromise, IV amiodarone is appropriate for acute rate control 9
The American College of Cardiology suggests oral amiodarone (200 mg daily maintenance) may be considered when ventricular rate cannot be adequately controlled at rest and during exercise with beta blockers, calcium channel blockers, or digoxin, alone or in combination, with a Class IIb recommendation 6, 7

The American Heart Association recommends amiodarone as a first-line antiarrhythmic choice in patients with heart failure, severe left ventricular hypertrophy, coronary artery disease, or prior myocardial infarction, although this is not directly cited, a similar recommendation is made for second-line use 10

The American College of Cardiology recommends a loading phase of 800 mg daily orally for 1 week, followed by a maintenance dose of 200 mg daily (or 100-200 mg daily using lowest effective dose) for rhythm control/cardioversion 7, 11
For acute IV cardioversion, 150 mg IV over 10 minutes, followed by continuous infusion (900-3000 mg daily) is recommended 11

The American College of Cardiology notes that amiodarone can cause pulmonary toxicity, thyroid dysfunction, ocular toxicity, hepatotoxicity, and cardiac effects, including bradycardia, heart block, and QTc prolongation 7

The American Heart Association warns that concomitant use of amiodarone with other QTc-prolonging drugs increases the risk of torsade de pointes 10
The American College of Cardiology recommends reducing warfarin dose by one-third to one-half when starting amiodarone, and monitoring INR closely to prevent serious or fatal bleeding, although this is not directly cited, a similar warning is made for digoxin 8

The American College of Cardiology recommends preoperative amiodarone to reduce incidence of AF after cardiac surgery, with a Class IIa recommendation 8, 9